AI and ML research outputs

FDA shipped Elsa 4.0 and the HALO data platform in May 2026 — an internal AI upgrade, not a sponsor-facing one. Here is what changed and what did not.

FDA’s April 2026 RFI sought input on an AI-enabled early-phase trials pilot. Comment window closed June 29, 2026 — here’s what it covered.

A BMJ study used a BERT classifier to screen 2.6 million cancer papers, flagging 9.9% as suspected paper-mill output — a scale manual review cannot match.

NeurIPS 2026 has made the Machine Learning Reproducibility Challenge an official track, with TMLR-accepted papers presented in Sydney this December.

EACL 2026’s call for papers confirms that submissions missing a dedicated Limitations section are desk rejected without review — a completeness check, not a quality judgment, that flows from ACL Rolling Review’s shared policy across the ACL, EMNLP, and NAACL submission pipeline.

Agents4Science 2025, organized by researchers at Stanford and Together AI, ran as a one-day virtual conference on October 22, 2025 with an unusual submission rule: an AI system had to be the paper’s primary author, generating the hypotheses, running the experiments, and writing the manuscript, with a human listed as a supervising co-author. It is one of the most concrete tests to date of how authorship credit and disclosure norms hold up when the ‘researcher’ doing the work is an AI agent.

Zochi (Intology) and Sakana’s AI Scientist each passed real peer review in 2025 — one at ACL, one at an ICLR workshop. What it means for authorship.

Senate Judiciary July 14, 2026 hearing on PERA (S.1546) weighed patent eligibility for diagnostics and AI — key stakes for university tech transfer.

HORIZON-ZEN+, a CERN-coordinated EU project (2025-2027), adds AI-assisted curation and discovery tools to Zenodo’s EU Open Research Repository.

OSTP’s July 2026 report and FY2028 memo direct agencies to fund researchers over institutions and diversify grants beyond peer review.

MDPI’s multi-year Proofig AI deal and ASM’s Imagetwin pilot data show AI image-forensics screening becoming standard in publisher editorial workflows.

Wiley disclosed $49M in FY2026 AI licensing revenue ($110M lifetime). Taylor & Francis and Springer Nature show similar deals; small publishers see little.

NeurIPS 2026 desk-rejected 178 position papers (18.4%) via the Pangram AI detector, no appeal allowed. What is verified, what is disputed, and why it matters.